Long-term topical management of psoriasis: the road ahead

References

• Feldman SR, Goffe B, Rice G, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504–513.
   PubMed Web of Science ®Google Scholar
• Kontochristopoulos G, Kouris A, Chantzaras A, et al. Improvement of health-related quality of life and adherence to treatment with calcipotriol-betamethasone dipropionate gel in patients with psoriasis vulgaris. An Bras Dermatol. 2016;91(2):160–166.
   PubMed Web of Science ®Google Scholar
• Segaert S, Shear NH, Chiricozzi A, et al. Optimizing anti-inflammatory and immunomodulatory effects of corticosteroid and vitamin D analogue fixed-dose combination therapy. Dermatol Ther). 2017;7(3):265–279.
   Web of Science ®Google Scholar
• Nast A, Boehncke WH, Mrowietz U, et al. S3-guidelines for the treatment of psoriasis vulgaris Update 2011. J Dtsch Dermatol Ges. 2011;9(Suppl 2):S1–S95.
   PubMed Web of Science ®Google Scholar
• Stein Gold LF. Topical therapies for psoriasis: improving management strategies and patient adherence. Semin Cutan Med Surg. 2016;35(2 Suppl 2):S36–S44.
   PubMedGoogle Scholar
• Menter A, Korman NJ, Elmets CA, et al. American academy of dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–659.
   PubMed Web of Science ®Google Scholar
• Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults. A national clinical guideline. 2010 [cited 2019 Nov 1]. Available from: http://www.sign.ac.uk/assets/sign121.pdf.
   Google Scholar
• National Institute for Health and Care Excellence. Psoriasis: assessment and management 2012 [cited 2019 Nov 1]. Available from: https://www.nice.org.uk/Guidance/CG153.
   Google Scholar
• Bagel J, Gold LS. Combining topical psoriasis treatment to enhance systemic and phototherapy: a review of the literature. J Drugs Dermatol. 2017;16(12):1209–1222.
   PubMed Web of Science ®Google Scholar
• Bagel J. Treat to target in psoriasis: a real-world experience with biologics and adjunctive topical therapy. J Drugs Dermatol. 2018;17(8):918.
   PubMed Web of Science ®Google Scholar
• Nast A, Boehncke WH, Mrowietz U, et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2012;304(2):87–113.
   PubMed Web of Science ®Google Scholar
• Imafuku S, Zheng M, Tada Y, et al. Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. J Dermatol. 2018;45(7):805–811.
   PubMed Web of Science ®Google Scholar
• Paul C, Gallini A, Archier E, et al. Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):1–10.
   PubMedGoogle Scholar
• Augustin M, Mrowietz U, Bonnekoh B, et al. Topical long-term therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. J Dtsch Dermatol Ges. 2014;12(8):667–682.
   Web of Science ®Google Scholar
• Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am Fam Physician. 2000;61(3):725–733.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Lynde CW, Kleyn CE, et al. Identification of key research needs for topical therapy treatment of psoriasis – a consensus paper by the International Psoriasis Council. J Eur Acad Dermatol Venereol. 2016;30(7):1115–1119.
   PubMed Web of Science ®Google Scholar
• Mrowietz U. Implementing treatment goals for successful long-term management of psoriasis. J Eur Acad Dermatol Venereol. 2012;26(Suppl 2):12–20.
   PubMed Web of Science ®Google Scholar
• Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645–648.
   PubMed Web of Science ®Google Scholar
• Gulliver W, Lynde C, Dutz JP, et al. Think beyond the skin: 2014 Canadian expert opinion paper on treating to target in plaque psoriasis. J Cutan Med Surg. 2015;19(1):22–27.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Reitamo S, Atzori F, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;63(6):742–750.
   Web of Science ®Google Scholar
• Thaçi D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008;159(6):1348–1356.
   PubMed Web of Science ®Google Scholar
• Lynde CW, Beecker J, Dutz J, et al. Treating to target(s) with interleukin-17 inhibitors. J Cutan Med Surg. 2019;23(Suppl 2):3S–34S.
   Google Scholar
• Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132.
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Jaworski JC, Kaiser JD, et al. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatrics. 2016;16:75.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2019. DOI:https://doi.org/10.1111/bjd.18333. [Epub ahead of print]
   Google Scholar
• Walsh JA, McFadden M, Woodcock J, et al. Product of the physician global assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol. 2013;69(6):931–937.
   PubMed Web of Science ®Google Scholar
• Walsh JA, Jones H, Mallbris L, et al. The physician global assessment and body surface area composite tool is a simple alternative to the psoriasis area and severity index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. Psoriasis (Auckl). 2018;8:65–74.
   PubMed Web of Science ®Google Scholar
• Duffin KC, Papp KA, Bagel J, et al. Evaluation of the physician global assessment and body surface area composite tool for assessing psoriasis response to apremilast therapy: results from ESTEEM 1 and ESTEEM 2. J Drugs Dermatol. 2017;16(2):147–153.
   PubMed Web of Science ®Google Scholar
• Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(5):861–867.
   PubMed Web of Science ®Google Scholar
• Schlager JG, Rosumeck S, Werner RN, et al. Topical treatments for scalp psoriasis: summary of a Cochrane systematic review. Br J Dermatol. 2017;176(3):604–614.
   PubMed Web of Science ®Google Scholar
• Saraceno R, Camplone G, D'Agostino M, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatolog Treat. 2014;25(1):30–33.
   PubMed Web of Science ®Google Scholar
• Bagel J, Zapata J, Nelson E. A prospective, open-label study evaluating adjunctive calcipotriene 0.005%/betamethasone dipropionate 0.064% foam in psoriasis patients with inadequate response to biologic therapy. J Drugs Dermatol. 2018;17(8):845–850.
   PubMed Web of Science ®Google Scholar
• Lambert J, Hol CW, Vink J. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study. J Eur Acad Dermatol Venereol. 2015;29(12):2349–2355.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Lu M, Veverka KA, et al. The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment. J Dermatolog Treat. 2019;30(5):446–453.
   PubMed Web of Science ®Google Scholar
• Perrone V, Sangiorgi D, Buda S, et al. Topical medication utilization and health resources consumption in adult patients affected by psoriasis: findings from the analysis of administrative databases of local health units. Clinicoecon Outcomes Res. 2017;9:181–188.
   PubMed Web of Science ®Google Scholar
• Reich K, Zschocke I, Bachelez H, et al. PSO-TOP study group. A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). Br J Dermatol. 2017;177(1):197–205.
   PubMed Web of Science ®Google Scholar
• NCT03402828. 2018 [cited 2019 Nov 01]. Available from: https://clinicaltrials.gov/ct2/show/NCT03402828.
   Google Scholar
• NCT02899962. 2019 [cited 2019 Nov 01].Available from: https://clinicaltrials.gov/ct2/show/NCT02899962.
   Google Scholar
• Pinter A, Thormann H, Angeletti F, et al. Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature. Clin Cosmet Investig Dermatol. 2018;11:451–459.
   PubMed Web of Science ®Google Scholar
• Gerdes S, Krakor M, Anger T, et al. Prospective, observational, non-interventional, multicentre study on the efficacy and tolerability of a new calcipotriol/betamethasone aerosol foam (Enstilar®) in patients with plaque psoriasis under daily practice conditions. Dermatology. 2017;233(6):425–434.
   PubMed Web of Science ®Google Scholar
• NCT0293558242. 2019 [cited 2019 Nov 01]. Available from: https://clinicaltrials.gov/ct2/show/NCT02935582.
   Google Scholar
• Girolomoni G, Calzavara Pinton P, Cristaudo A, et al. Back to the future: a new topical approach for mild-to-moderate psoriasis. G Ital Dermatol Venereol. 2018;153(3):375–382.
   PubMed Web of Science ®Google Scholar
• Zschocke I, Mrowietz U, Karakasili E, et al. Non-adherence and measures to improve adherence in the topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 2014;28(Suppl 2):4–9.
   PubMed Web of Science ®Google Scholar
• Alinia H, Moradi Tuchayi S, Smith JA, et al. Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. Br J Dermatol. 2017;176(3):759–764.
   PubMed Web of Science ®Google Scholar
• Strober BE, van der Walt JM, Armstrong AW, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther (Heidelb)). 2019;9(1):5–18.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. Am J Clin Dermatol. 2009;10(6):397–406.
   PubMed Web of Science ®Google Scholar
• Svendsen MT, Andersen F, Andersen KH, et al. A smartphone application supporting patients with psoriasis improves adherence to topical treatment: a randomized controlled trial. Br J Dermatol. 2018;179(5):1062–1071.
   PubMed Web of Science ®Google Scholar
• Puig L, Carrascosa JM, Belinchón I, et al. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104(6):488–496.
   PubMedGoogle Scholar
• Torsekar R, Gautam MM. Topical therapies in psoriasis. Indian Dermatol Online J. 2017;8(4):235–245.
   PubMedGoogle Scholar
• Feldman SR. Improving adherence to topical treatment. Cutis. 2009;83(4):215–217.
   PubMed Web of Science ®Google Scholar
• Iversen L, Dauden E, Segaert S, et al. Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. J Eur Acad Dermatol Venereol. 2017;31(8):1271–1284.
   PubMed Web of Science ®Google Scholar
• Sidgiddi S, Pakunlu RI, Allenby K. Efficacy, safety, and potency of betamethasone dipropionate spray 0.05%: a treatment for adults with mild-to-moderate plaque psoriasis. J Clin Aesthet Dermatol. 2018;11(4):14–22.
   PubMedGoogle Scholar
• Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb)). 2016;6(3):413–425.
   PubMed Web of Science ®Google Scholar
• Basse LH, Olesen M, Lacour JP, et al. Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle. J Invest Dermatol. 2014;134(Suppl 2):192.
   PubMedGoogle Scholar
• Iversen L, Jakobsen HB. Patient preferences for topical psoriasis treatments are diverse and dificult to predict. Dermatol Ther (Heidelb)). 2016;6(2):273–285.
   PubMed Web of Science ®Google Scholar
• Young M, Aldredge L, Parker P. Psoriasis for the primary care practitioner. J Am Assoc Nurse Pract. 2017;29(3):157–178.
   PubMed Web of Science ®Google Scholar
• Pathak SN, Scott PL, West C, et al. Self-management in patients with psoriasis. Psoriasis Targets Ther. 2014;4:19–26.
   Google Scholar
• Guenther LC. Fixed-dose combination therapy for psoriasis. Am J Clin Dermatol. 2004;5(2):71–77.
   PubMed Web of Science ®Google Scholar
• Stein Gold LF. Understanding topical therapies for psoriasis. Cutis. 2019;103(4S):S8–S12.
   PubMedGoogle Scholar
• Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013;28(3):CD005028.
   Google Scholar
• Neri L, Miracapillo A. Treatment adherence and real-life effectiveness of topical therapy in patients with mild or moderate psoriasis: uptake of scientific evidence in clinical practice and dermatologists’ preferences for alternative treatment options. G Ital Dermatol Venereol. 2015;150(1):19–26.
   PubMed Web of Science ®Google Scholar
• Mueller SM, Itin P, Vogt DR, et al. Assessment of “corticophobia” as an indicator of non-adherence to topical corticosteroids: a pilot study. J Dermatolog Treat. 2017;28(2):104–111.
   PubMed Web of Science ®Google Scholar
• Khosravi H, Siegel MP, Van Voorhees AS, et al. Treatment of inverse/intertriginous psoriasis: updated guidelines from the Medical Board of the National Psoriasis Foundation. J Drugs Dermatol. 2017;16(8):760–766.
   PubMed Web of Science ®Google Scholar
• Norsgaard H, Kurdykowski S, Descargues P, et al. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. Arch Dermatol Res. 2014;306(8):719–729.
   PubMed Web of Science ®Google Scholar
• Taheri A, Cantrell J, Feldman SR. Tachyphylaxis to topical glucocorticoids; what is the evidence? Dermatol Online J. 2013;19(7):18954.
   PubMedGoogle Scholar
• Czarnowicki T, Linkner RV, Suárez-Fariñas MJ, et al. An investigator-initiated, double-blind, vehicle-controlled pilot study: assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis. Am Acad Dermatol. 2014;71(5):954–959.
   PubMed Web of Science ®Google Scholar
• Miller JJ, Roling D, Margolis D, et al. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol. 1999;41(4):546–549.
   PubMed Web of Science ®Google Scholar
• Sawyer L, Samarasekera EJ, Wonderling D, et al. Topical therapies for the treatment of localized plaque psoriasis in primary care: a cost-effectiveness analysis. Br J Dermatol. 2013;168(5):1095–1105.
   PubMed Web of Science ®Google Scholar
• Lanati EP, Orlando VL. Cost effectiveness analysis of the use of Enstilar compared to Dovobet gel in the treatment of psoriasis in Italy. ISPOR. 2017;20(9):PA804.
   Google Scholar
• Kivelevitch D, Frieder J, Watson I, et al. Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas. Expert Opin Pharmacother. 2018;19(6):561–575.
   PubMed Web of Science ®Google Scholar
• Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol. 2014;70(5):871–881.
   PubMed Web of Science ®Google Scholar